Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Lantheus Holdings Inc Stock Research

LNTH

65.27USD+0.65(+1.01%)Market Closed
Watchlist

Market Summary

USD65.27+0.65
Market Closed
1.01%

LNTH Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

LNTH Stock Price

LNTH RSI Chart

LNTH Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

136.43

Price/Sales (Trailing)

4.05

EV/EBITDA

53.45

Price/Free Cashflow

16.55

LNTH Price/Sales (Trailing)

LNTH Profitability

EBT Margin

-4.12%

Return on Equity

-3.97%

Return on Assets

-1.31%

Free Cashflow Yield

6.04%

LNTH Fundamentals

LNTH Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

43.79%

Revenue Q/Q

6.95%

LNTH Earnings

Earnings (TTM)

33.4M

Earnings Y/Y

118.61%

Earnings Q/Q

3.5K%

Price Action

52 Week Range

47.46100.85
(Low)(High)

Last 7 days

3.2%

Last 30 days

-1.7%

Last 90 days

-22.8%

Trailing 12 Months

-2%

LNTH Financial Health

Current Ratio

2.8

Debt/Equity

1.25

Debt/Cashflow

0.68

LNTH Investor Care

Shares Dilution (1Y)

1.57%

Diluted EPS (TTM)

0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for LNTH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Niedzwiecki Daniel
acquired
50,630
17.79
2,846
see remarks
2023-09-15
Niedzwiecki Daniel
sold
-189,060
66.43
-2,846
see remarks
2023-08-29
Marshall Robert J. Jr.
acquired
-
-
4,872
cfo and treasurer
2023-08-21
Blanchfield Paul
sold
-26,968
66.1
-408
president
2023-08-18
Blanchfield Paul
sold
-97,785
65.19
-1,500
president
2023-08-15
Marshall Robert J. Jr.
sold
-685,200
68.52
-10,000
cfo and treasurer
2023-08-11
Heino Mary Anne
sold
-750,981
68.5828
-10,950
ceo
2023-08-11
Niedzwiecki Daniel
sold
-291,895
67.93
-4,297
see remarks
2023-07-19
Sabens Andrea
sold
-159,210
90.873
-1,752
chief accounting officer
2023-07-18
Blanchfield Paul
sold (taxes)
-45,273
87.4
-518
president

1–10 of 50

Which funds bought or sold LNTH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-14.91
-1,084,000
6,935,000
-%
2023-09-12
Prosperity Financial Group, Inc.
added
6.89
18,660
234,472
0.21%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
68.00
4,196
-%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
new
-
9,903
9,903
-%
2023-08-24
Alberta Investment Management Corp
sold off
-100
-2,183,220
-
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-32.74
-438,712
948,296
0.01%
2023-08-22
COMERICA BANK
new
-
-
-
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
18,294
18,294
0.01%
2023-08-21
VitalStone Financial, LLC
new
-
696,000
696,000
0.39%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.77
-155,002
6,936,320
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying LNTH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LNTH
No. of Funds

Schedule 13G FIlings of Lantheus Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
10.53%
7,247,124
SC 13G/A
Jan 26, 2023
blackrock inc.
11.9%
8,203,470
SC 13G/A
Jan 20, 2023
blackrock inc.
11.9%
8,203,470
SC 13G/A
Jul 11, 2022
vanguard group inc
10.84%
7,438,724
SC 13G/A
Feb 15, 2022
armistice capital, llc
0%
0
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
3.1%
2,165,371
SC 13G/A
Feb 04, 2022
wellington trust co n a
1.73%
1,171,449
SC 13G/A
Jan 27, 2022
blackrock inc.
15.8%
10,675,397
SC 13G/A
Jan 25, 2022
blackrock inc.
15.8%
10,675,397
SC 13G
Dec 10, 2021
wellington management group llp
4.96%
3,358,378
SC 13G/A

Recent SEC filings of Lantheus Holdings

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Aug 31, 2023
4
Insider Trading
Aug 28, 2023
8-K
Current Report
Aug 23, 2023
4
Insider Trading
Aug 22, 2023
4
Insider Trading
Aug 21, 2023
144
Notice of Insider Sale Intent
Aug 18, 2023
144
Notice of Insider Sale Intent
Aug 18, 2023
8-K
Current Report
Aug 17, 2023
4
Insider Trading

Peers (Alternatives to Lantheus Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.5B
30.4B
-3.24% -5.78%
28.7
6.01
-1.49% 0.14%
167.5B
40.2B
-7.66% -3.16%
32.45
4.16
-11.68% -39.67%
105.0B
31.6B
-3.94% -2.93%
28.96
3.33
1.57% -30.40%
35.9B
3.5B
-12.23% 30.55%
45.38
10.22
6.21% 19.20%
27.7B
2.9B
-4.66% 48.48%
53.48
9.68
-2.14% -24.34%
MID-CAP
9.4B
937.8M
-2.31% 34.57%
323.13
10.04
16.30% 250.21%
4.6B
1.1B
-1.66% -2.00%
136.43
4.05
69.36% 3.03%
4.0B
822.4M
-18.24% 27.75%
-175.87
4.89
56.01% -147.34%
-
-
-8.05% -1.80%
-
-
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.2B
254.9M
2.45% 31.18%
-62.25
4.89
-1.22% 15.74%
653.5M
240.7M
-5.45% -44.20%
-15.31
2.72
4.82% 85.44%
45.4M
9.0M
55.81% -7.21%
-2.52
5.03
20.81% 50.13%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

Lantheus Holdings News

Nasdaq
Lantheus Holdings (LNTH) Gains As Market Dips: What You Should ....
Nasdaq,
8 hours ago
Zacks Investment Research
DirectorsTalk Interviews
Yahoo Finance

Returns for LNTH

Cumulative Returns on LNTH

34.4%


7-Year Cumulative Returns

35.0%


5-Year Cumulative Returns

74.9%


3-Year Cumulative Returns

Risks for LNTH

What is the probability of a big loss on LNTH?

89.6%


Probability that Lantheus Holdings stock will be more than 20% underwater in next one year

61.1%


Probability that Lantheus Holdings stock will be more than 30% underwater in next one year.

39.2%


Probability that Lantheus Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LNTH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Lantheus Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Lantheus Holdings

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue9.5%1,1251,027935801664542425390376341339335332352347344347347343338329
Gross Profit12.2%594530582472368276188168162142139145150169175174177177175169163
Operating Expenses-----------143---123---110--
  S&GA Expenses8.0%12111310093.0084.0075.0068.0062.0056.0045.0041.0038.0037.0042.0042.0041.0042.0043.0043.0044.0043.00
  R&D Expenses0.4%33133031251.0049.0047.0045.0046.0047.0039.0033.0025.0018.0019.0020.0020.0020.0018.0017.0016.0016.00
EBITDA-100.0%-19.0082.0021611421.00-25.009.0019.0037.0023.0022.0029.0045.0056.00------
EBITDA Margin-100.0%-0.02*0.09*0.27*0.17*0.04*-0.06*0.02*0.05*0.11*0.07*0.07*0.09*0.13*0.16*------
Interest Expenses32.5%14.0011.007.006.006.007.008.009.0010.0010.009.009.008.0011.0014.0016.0018.0018.0017.0017.0017.00
Earnings Before Taxes145.8%19.00-42.2927.0016259.00-31.48-75.04-36.87-24.50-2.67-11.48-6.247.0021.0029.0039.0046.0050.0050.0048.0045.00
EBT Margin100.0%--0.04*0.03*0.20*0.09*-0.06*-0.18*-0.09*-0.07*-0.01*-0.03*-0.02*0.02*0.06*0.08*------
Net Income288.5%33.00-17.7028.0010732.00-37.33-71.28-34.48-27.45-7.80-13.470.0012.0025.0032.0035.0039.0042.0041.00124124
Net Income Margin100.0%--0.02*0.03*0.13*0.05*-0.07*-0.17*-0.09*-0.07*-0.02*-0.04*0.00*0.04*0.07*0.09*------
Free Cashflow-100.0%-38028219010154.0054.0041.0045.0017.0016.0038.0056.0079.0080.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.9%1,3381,3491,3211,0961,014933864848858843870880880404406402390444440425402
  Current Assets-2.7%752773678502404325236202186168184185181180173154140195195191167
    Cash Equivalents-12.1%41447141625717110510191.0092.0069.0080.0088.0090.0096.0093.0078.0057.0011211310586.00
  Inventory22.9%52.0042.0035.0035.0034.0034.0035.0034.0032.0030.0036.0038.0035.0031.0029.0031.0032.0032.0033.0035.0031.00
  Net PPE--------------10911611411311210899.0097.00
  Goodwill0%61.0061.0061.0061.0061.0061.0061.0061.0061.0061.0059.0058.0045.0016.0016.0016.0016.0016.0016.0016.0016.00
Liabilities-13.1%785904874458446417399348350315356366364286291301298361369369357
  Current Liabilities-44.3%15427624823621917890.0077.0074.0065.0081.0082.0076.0062.0066.0060.0053.0043.0053.0055.0043.00
  Long Term Debt0.1%559559558152156159163167169-198----------
    LT Debt, Current-9.0%0.000.000.0015.0014.0013.0012.0010.0010.0010.0021.0018.0017.0010.0010.0010.0010.003.003.003.003.00
    LT Debt, Non Current---558---163--171198205210181184186189263264264265
Shareholder's Equity24.0%55344644763856751646449950852851451451611811510192.0083.0071.0056.0045.00
  Retained Earnings48.0%-101-195-193-73.97-135-178-221-181-167-140-149-146-140-133-136-146-151-158-168-181-190
  Additional Paid-In Capital1.8%730717716708700692685681676670666662658254252249245242240238236
Shares Outstanding0.2%70.0070.0069.0069.0069.0068.0068.0068.0068.0067.0067.0067.0043.0039.0039.0039.0039.0039.0039.0038.0038.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-27.6%27538028219010154.0054.0041.0045.0017.0016.0038.0056.0079.0080.0075.0073.0072.0061.0057.0048.00
  Share Based Compensation15.9%39.0033.0029.0025.0021.0018.0016.0015.0016.0014.0014.0013.0013.0013.0012.0012.0011.0010.009.009.008.00
Cashflow From Investing-5.1%-336-319-276-16.37-12.70-11.014.004.003.0011.00-4.91-5.87-5.47-14.21-22.06-24.69-26.35-28.55-19.13-17.72-16.00
Cashflow From Financing-0.7%303305312-8.25-8.02-6.72-39.33-41.60-47.15-52.92-21.86-20.31-14.94-81.38-78.88-76.99-76.31-5.19-4.67-2.58-2.89
  Buy Backs---75.00------------------

LNTH Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenues$ 321,700$ 223,723$ 622,484$ 432,603
Cost of goods sold119,05385,694342,761165,504
Gross profit202,647138,029279,723267,099
Operating expenses    
Sales and marketing36,45627,49269,07347,846
General and administrative26,15132,59849,42270,186
Research and development15,90114,73546,43326,938
Total operating expenses78,50874,825164,928144,970
Operating income124,13963,204114,795122,129
Interest expense4,9331,4699,9242,978
Other income(4,482)(310)(7,713)(795)
Income before income taxes123,68862,045112,584119,946
Income tax expense29,55718,98721,26033,926
Net income$ 94,131$ 43,058$ 91,324$ 86,020
Net income per common share:    
Basic (in dollars per share)$ 1.38$ 0.63$ 1.34$ 1.26
Diluted (in dollars per share)$ 1.33$ 0.61$ 1.31$ 1.22
Weighted-average common shares outstanding:    
Basic (in shares)68,37168,67468,06268,343
Diluted (in shares)71,01470,79669,95770,412

LNTH Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 414,076$ 415,652
Accounts receivable, net256,277213,397
Inventory51,80135,475
Other current assets22,90613,092
Assets held for sale7,1590
Total current assets752,219677,616
Property, plant and equipment, net129,981122,166
Intangibles, net221,004315,285
Goodwill61,18961,189
Deferred tax assets, net134,201110,647
Other long-term assets39,12634,355
Total assets1,337,7201,321,258
Current liabilities  
Current portion of long-term debt and other borrowings384354
Accounts payable38,86120,563
Short-term contingent liability099,700
Accrued expenses and other liabilities114,798127,084
Total current liabilities154,043247,701
Asset retirement obligations22,72922,543
Long-term debt, net and other borrowings559,235557,712
Other long-term liabilities49,06846,155
Total liabilities785,075874,111
Commitments and contingencies (See Note 18)
Stockholders’ equity  
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)00
Common stock ($0.01 par value, 250,000 shares authorized; 69,755 and 68,851 shares issued as of June 30, 2023 and December 31, 2022, respectively)698689
Additional paid-in capital729,733715,875
Treasury Stock at cost - 1,339 shares as of June 30, 2023 and December 31, 2022(75,000)(75,000)
Accumulated deficit(101,834)(193,158)
Accumulated other comprehensive loss(952)(1,259)
Total stockholders’ equity552,645447,147
Total liabilities and stockholders’ equity$ 1,337,720$ 1,321,258
Mary A. Heino
610
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.